Following today’s announcement from NHS England regarding the extension of the national HIV prevention programme with Public Health England, and funding for ten new specialised treatments the ABPI said:
"This latest announcement brings a welcome conclusion to NHS England's 2015/16 clinical policy decision making process. The 11 positive decisions will give many patients access to new medicines and treatments and we urge NHS England to ensure that patients get access as quickly as possible.
We echo Dr Fielden's comments that constructive joint working between NHS England and the pharmaceutical industry is essential to ensure that the system for specialised commissioning is transparent and fair so that it is understood and trusted by patients. NHS England is about to embark on the 2017/18 commissioning process, under which the three new treatments not funded today and future new treatments will be assessed, and we look forward to working together towards the joint goal of having a process that gets new medicines for all conditions to all patients that need them."
ABPI Press OfficeEmail: email@example.comTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.